Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047539 · ClinicalTrials.gov registry record · Early Phase 1
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT02047539 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants.
The verdict
NCT02047539, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR symptoms. As secondary measures the investigators aim to collect laboratory studies of inflammation markers and genetic samples to determine whether certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.
Interventions
- DRUG Placebo
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-01 |
| Est. Completion | 2021-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047539
The ClinicalTrials.gov registry entry for NCT02047539 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02047539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047539 about?
NCT02047539 is a clinical study titled "Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis". The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to determine whether it may delay or prevent the onset of psychosis in those currently experiencing CHR sympt...
What is the current status of trial NCT02047539?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2015-01. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02047539?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG).
Who is sponsoring clinical trial NCT02047539?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.